Rtw Investments 13F: Cuts TSHA Stake by $16M

RTW Investments has reduced its position in TSHA, according to its latest 13F filing with the SEC. The fund sold 2,718,049 shares, trimming its stake by 16.6% to 13,680,248 shares. As of the filing, these holdings were valued at approximately $78.1 million.

What Changed in RTW Investments' TSHA Position

RTW Investments cut its stake in TSHA from 16,398,297 shares to 13,680,248 shares, a decrease of 2,718,049 shares or 16.6%. The current value of its holdings is about $78.1 million.

Other Institutional Activity in TSHA

Several other funds also made moves in TSHA. RA Capital Management maintained its position with 23,555,648 shares valued at $105.3 million. Goldman Sachs Group significantly increased its holdings by 8,676,906 shares to a total of 22,369,645 shares, worth about $99.9 million. Avoro Capital Advisors held steady with 21,700,000 shares valued at $97 million. Meanwhile, BlackRock trimmed its position by 277,521 shares, ending with 18,365,608 shares worth $82.1 million. Vestal Point Capital boosted its stake by 4,250,000 shares, reaching 18,000,000 shares valued at $80.5 million.

Taysha Gene Therapies, Inc. Stock Up 13.7%

Shares of TSHA are trading at $5.71. The company has a market capitalization of approximately $78.1 million. TSHA lacks a meaningful P/E ratio as it is not currently profitable. The stock's 52-week range is not provided, but it is trading below its recent highs.

Insider Buying and Selling at Taysha Gene Therapies, Inc.

On June 1, 2026, several insiders made purchases in TSHA. John Stalfort III, Alison Long, and Laura Sepp-Lorenzo each bought 42,671 shares, while Laura Sepp-Lorenzo and John Stalfort III also purchased an additional 21,335 shares each. Phillip Donenberg acquired 21,335 shares as well. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

Analysts remain optimistic about TSHA. On April 6, 2026, Canaccord Genuity maintained a 'buy' rating with a price target of $17. Needham reiterated its 'buy' rating with a $12 target on March 20, while Chardan Capital also maintained a 'buy' with the same target on March 19. Overall, the consensus remains positive, with a mean target price reflecting strong potential upside.

About TSHA

TSHA operates in the biotechnology sector, focusing on developing gene therapies for the treatment of central nervous system disorders. The company is based in the United States and is engaged in research and development to address unmet medical needs in neurological conditions.

Bottom Line

RTW Investments' recent reduction in its TSHA holdings is part of a broader trend among institutional investors. These 13F filings are backward-looking and may not reflect current positions. Investors watch such movements for insights into fund strategies and market sentiment.